Form 4 for SLXN Silexion Therapeutics Corp
Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-20 · accession 0001178913-26-000600 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-23 | 2026-02-20 | SLXN | Hadar Ilan | COB, CEO, Dir | A - Grant | $0.00 | +64.3K | 65.5K | +5,740% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-02-20 | A | A | 64,350 | $0.00 | 65,471 | D | — | — | (F1) The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflects adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively. |